Pacific Biosciences Of California (PACB) Accumulated Expenses (2011 - 2026)

Pacific Biosciences Of California has reported Accumulated Expenses for 16 years, with the latest figure at $33.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 15.57% year-over-year to $33.9 million; the trailing twelve-month figure through Mar 2026 stood at $33.9 million (up 15.57% YoY), and the FY2025 full-year result was $33.6 million, up 48.91% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $33.9 million, up from $33.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $45.7 million in Q4 2023, with the low at $19.2 million in Q3 2024.
• Average Accumulated Expenses over 5 years is $27.5 million, with a median of $26.5 million recorded in 2025.
• Year-over-year, Accumulated Expenses jumped 5387.54% in 2022 and tumbled 50.57% in 2024.
• Tracing PACB's Accumulated Expenses over 5 years: stood at $32.6 million in 2022, then jumped by 40.23% to $45.7 million in 2023, then plunged by 50.57% to $22.6 million in 2024, then jumped by 48.91% to $33.6 million in 2025, then climbed by 0.77% to $33.9 million in 2026.
• The last three Accumulated Expenses figures came in at $33.9 million (Q1 2026), $33.6 million (Q4 2025), and $29.2 million (Q3 2025), per Business Quant data.

Peer Comparison